Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 1/20 | 0.68 |
| ▸ | CDK2 | P24941 | 1/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 8/20 | 0.61 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851097 | 0.84 | RET (0.67) | CCNE1CDK2GSK3BNOX4PDE4A | |
| SCHEMBL1851095 | 0.84 | RET (0.67) | CCNE1CDK2GSK3BNOX4PDE4A | |
| SCHEMBL13080904 | 0.84 | RET (0.67) | CCNE1CDK2GSK3BNOX4PDE4A | |
| SCHEMBL6683686 | 0.84 | CCNE1 (0.64) | CCNE1CDK2PLK4GSK3BNOX4 | |
| SCHEMBL5480412 | 0.81 | LRRK2 (0.78) | PLK4GSK3BLRRK2 | |
| SCHEMBL5480416 | 0.81 | LRRK2 (0.78) | PLK4GSK3BLRRK2 | |
| SCHEMBL13080514 | 0.80 | CCNE1 (0.66) | CCNE1CDK2GSK3BNOX4PDE4A | |
| SCHEMBL3754352 | 0.80 | NOX4 (0.67) | CCNE1CDK2GSK3BNOX4PDGFRB | |
| SCHEMBL3752053 | 0.80 | NOX4 (0.70) | CCNE1CDK2GSK3BNOX4PDE4A | |
| SCHEMBL3757258 | 0.79 | GSK3B (0.74) | CCNE1CDK2GSK3BNOX4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | claimed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | CCNE1 3889/4885CDK2 815/4885PLK4 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.